18/02/21 BARD1 CEO Dr Leearne Hinch is interviewed by Alan Kohler from The Eureka Report.
15/02/21 BARD1 Life Sciences reveals its SubB2M technology can detect all stages of breast cancer from a blood sample, 100% specificity and 95% sensitivity.
03/09/20 BARD1 AWARDED BIOMEDICAL TRANSLATION BRIDGE FUNDING TO DEVELOP BREAST CANCER TESTS
MTP Connect – Biomedical Translation Bridge Program
24/04/20: BARD1 Life Sciences Limited was represented at the AACR Annual Meeting 2020 by CSO Dr Irmgard Irminger-Finger who gave an invited oral presentation on 24 April 2020.
Title: A BARD1 autoimmune antibodies test for early detection of ovarian cancer.
Session Title: Translational Prevention Studies
The American Association of Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer.
The AACR held its Annual Meeting 2020 under the leitmotif Turning Science into Lifesaving Care
The AACR Annual Meeting 2020 was scheduled for 24-29 April 2020 in San Diego, California, but was held as the AACR Virtual Annual Meeting 2020.
2/1/17 Interview of BARD1 LSL Executive Director and CSO Dr Irmgard Irminger-Finger by Startwerk “BARD1AG SA: The real fight against lung cancer” https://www.startwerk.ch/2017/01/31/bard1ag-sa-the-real-fight-against-lung-cancer/
5/12/16 BARD1 Life Sciences Limited (ASX:BD1) advises that it has relocated its headquarters to the Harry Perkins Institute of Medical Research (the Perkins) at QEII Medical Centre in Nedlands, Western Australia. The Perkins houses world-class research teams, latest equipment and state-of-the-art facilities that will enable BARD1 to collaborate with Perkins’ researchers to expand its research programs in cancer diagnostics and therapeutics. BARD1’s Registered Office remains unchanged at the Subiaco address.